A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
Article in European Journal of Cancer (March 2024)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Article in European Journal of Cancer (March 2024)
Article in The Cancer Journal (March 2024)
Article in Frontiers in Oncology (February 2024)